Physician profile
Jonathan D Davis
NPI 1538303276
$2,311.92
in general payments reported to CMS, 2019-2025
10 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $1,074 · 2022: $304 · 2023: $78.07 · 2024: $300 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,605.06 | 2020-2025 | |
| Abbott Laboratories | $370.68 | 2019-2024 | Gallant |
| Abiomed | $110.48 | 2025 | |
| Kestra Medical Technology Services, INC. | $84.10 | 2024 | Assure Wcd |
| Esperion Therapeutics, INC. | $40.09 | 2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.10 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.73 | 2022 | |
| Edwards Lifesciences Corporation | $22.27 | 2024 | Pascal |
| Pfizer INC. | $19.41 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.